EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer

Yueren Yan, Ning Wang, Bowen Xing, Min Yang, Jun Shang, Yufang Bao, Lixing Xiao, Ningxia Zhang, Yunpeng Ren, Chunnan Liu, Yuting Chen, Han Han und 8 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202503322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yueren Yan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. Hauptthemen laut MEDLINE: rac1 GTP-Binding Protein, Lung Neoplasms, Carcinogenesis, Adenocarcinoma of Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Strategic Priority Research Program of Chinese Academy of Sciences, Innovation Research Team of High-level Local Universities in Shanghai, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulated RNA splicing has emerged as a pervasive yet understudied feature of cancer. The small GTPase RAC1 undergoes splicing changes in multiple cancers. However, the in vivo functional disparities between the two major RAC1 isoforms, RAC1B and the canonical RAC1A, and their therapeutic implications in cancer remain largely unexplored. Here, RAC1B is found to be significantly upregulated in lung adenocarcinoma (LUAD) patients, particularly in those harboring EGFR mutations. Through isoform‐specific overexpression and depletion assays in murine and cellular models of EGFR ‐mutant LUAD, it is revealed that RAC1B, but not RAC1A, promotes LUAD cell proliferation and tumor growth. Mechanistically, RAC1B stabilizes EGFR by inhibiting its lysosome trafficking and degradation. This function is mediated by the specific binding of RAC1B to the guanine nucleotide exchange factor GDS1, which activates RAC1B. The splicing factor RBM10 which is frequently mutated in LUAD is further identified as a negative regulator of RAC1B . Importantly, utilizing LUAD patient‐derived organoid and xenograft models, it is demonstrated that targeting RAC1B potently suppresses tumor growth and enhances the efficacy of EGFR inhibitors. Together, the findings delineate functional differences and underlying mechanisms of RAC1 isoforms in LUAD tumorigenesis, highlighting a promising therapeutic route via targeting RAC1B for lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rac1 GTP-Binding ProteinLung NeoplasmsCarcinogenesisAdenocarcinoma of LungRNA SplicingHumansAnimalsMiceCell Line, TumorCell ProliferationErbB Receptors

Stichwörter der Autor:innen

EGFRRAC1RAC1Blung cancersplicing dysregulation

Substanzen

rac1 GTP-Binding ProteinRAC1 protein, humanErbB Receptors

Autor:innen und Institutionen

  • Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Institute of Thoracic Oncology, Fudan University, Shanghai, 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
  • Department of Cellular and Genetic Medicine, School of Basic Medical Sciences & Minhang Hospital, Fudan University, Shanghai, 200032, China.
  • University of Chinese Academy of Sciences, CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, 200031, China.
  • Department of Pharmacology, School of Basic Medical Sciences & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, 200032, China.

ORCID-Profile: Yongbo Wang

Förderung

  • Strategic Priority Research Program of Chinese Academy of Sciences
  • Innovation Research Team of High-level Local Universities in Shanghai
  • National Natural Science Foundation of China
  • Shanghai Municipal Natural Science Fund
  • Shanghai Institute for Advanced Study of Zhejiang University
  • National Key Research and Development Program of China
  • NCI NIH HHS

Zitieren

APA

Yan, Y., Wang, N., Xing, B., Yang, M., Shang, J., Bao, Y., Xiao, L., Zhang, N., Ren, Y., Liu, C., Chen, Y., Han, H., Pan, Y., Lv, L., Zong, W. X., Ji, H., Zhan, C., Wang, Z., Chen, H., & Wang, Y. (2025). Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.202503322

Vancouver

Yan Y, Wang N, Xing B, Yang M, Shang J, Bao Y, et al. Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer. Advanced Science. 2025. doi:10.1002/advs.202503322

BibTeX
@article{Yan2025,
  author = {Yan, Yueren and Wang, Ning and Xing, Bowen and Yang, Min and Shang, Jun and Bao, Yufang and Xiao, Lixing and Zhang, Ningxia and Ren, Yunpeng and Liu, Chunnan and Chen, Yuting and Han, Han and Pan, Yunjian and Lv, Lei and Zong, Wei-Xing and Ji, Hongbin and Zhan, Changyou and Wang, Zefeng and Chen, Haiquan and Wang, Yongbo},
  title = {Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202503322}
}
Kostenlos starten →